Research image darker c2.jpg

Amyloidosis Research Consortium

Accelerating the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation


 
AmyloidHomeHeart
 

Rare, Underserved and Underdiagnosed

 

Amyloidosis is a disorder caused by proteins that possess abnormal conformational features leading them to aggregate and infiltrate tissues in the form of amyloid fibrils. Systemic amyloidosis is a disease that can damage the heart, kidneys, liver, soft tissue and nervous system, resulting in multi-organ failure and death. 

Awareness and understanding of these diseases is the first step to delivering better outcomes for patients.

 
 
AmyloidHomeButterfly
 

Transform the Research Landscape

 

The Amyloidosis Research Consortium has been established to address critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. 

ARC is addressing the urgent, unmet medical needs in amyloidosis.

 
 
AmyloidHomeHeart
 

Optimize, Collaborate and Share

 

Our Collaborative Network speeds the delivery of new and better therapies to patients with amyloidosis.  This network consists of a highly collaborative team of core amyloidosis centers, devoted to all the types of systemic amyloidosis. 

Find out more about our Clinical Trials Network and Core Member Centers.

 
 
AmyloidHomeHeart
 

Deliver Actionable Solutions for Patients

 

As a patient led organization ARC has firsthand knowledge of how amyloidosis affects our community. We engage scientists, policymakers and government regulators as partners in our efforts to breakdown barriers to research and drug development. 

Scientific progress is maximized when supported by sound public policy and advocacy.